Beresford, Mark, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Hudson, Zoe, Carucci, Margherita, Ingarfield, Kate, Gee, Julia ORCID: https://orcid.org/0000-0001-6483-2015, Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Kitson, Terri ORCID: https://orcid.org/0000-0001-6333-046X, Alchami, Fouad, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Hayward, Larrie, Hwang, David, Spensley, Saiqa, Waters, Simon, Wheatley, Duncan and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1 (1) , 13. 10.1038/s44276-023-00016-8 |
Kitson, Terri ORCID: https://orcid.org/0000-0001-6333-046X, Osborne, Emma, Noble, Simon ORCID: https://orcid.org/0000-0001-5425-2383, Pease, Nikki, Alikhan, Raza, Bryant, Catherine, Groves, Tristan, Wallace, Rebecca, Walker, Sarah, Seddon, Kathy, Smith, Deb, Raisanen, Lawrence, Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Thomas, Ian, Upton, Laura and Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13 (9) , e073049. 10.1136/bmjopen-2023-073049 |
Geldart, Thomas, Chester, John ORCID: https://orcid.org/0000-0002-7830-3840, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Crabb, Simon, Elliott, Tony, Protheroe, Andrew, Huddart, Robert A., Mead, Graham, Barber, Jim, Jones, Robert J., Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Cowles, Robert, Evans, Jessica and Griffiths, Gareth 2015. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67 (4) , pp. 599-602. 10.1016/j.eururo.2014.11.003 |
Noble, Simon, Smith, Joanna D., Baillie, Jessica, Baglin, T., Griffiths, Gareth O., Casbard, Angela, Cohen, Deborah, Fitzmaurice, D., Hood, Kerenza, Rose, P., Cohen, A., Johnson, Miriam, Maraveyas, A., Bell, John, Toone, H. and Nelson, Annmarie 2014. ALICAT: Anticoagulation length in cancer associated thrombosis - a mixed-methods feasibility study. Thrombosis Research 133 (Supp 2) , S220-S220. 10.1016/S0049-3848(14)50032-1 |
Smith, Joanna D. ORCID: https://orcid.org/0000-0003-4234-6686, Baillie, Jessica ORCID: https://orcid.org/0000-0002-4592-7286, Baglin, Trevor, Griffiths, Gareth O., Casbard, Angela C. ORCID: https://orcid.org/0000-0001-6241-3052, Cohen, David, Fitzmaurice, David A., Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631, Rose, Peter, Cohen, Alexander T., Johnson, Miriam, Maraveyas, Anthony, Bell, John, Toone, Harold, Nelson, Annmarie ORCID: https://orcid.org/0000-0002-6075-8425 and Noble, Simon Ian Robert ORCID: https://orcid.org/0000-0001-5425-2383 2014. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study. Trials 15 (1) , 122. 10.1186/1745-6215-15-122 |